Drugs / NUVISERTIB
NUVISERTIB
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07492355 | Mar → May 2024 | myelofibrosis | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06389955 | May → Aug 2023 | — | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03715504 | Apr 2019 → Mar 2021 | cancer | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-03-18 | Jazz Pharmaceuticals | Results Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026 jazzpharma.com ↗
Nuvisertib (TP-3654) and Dordaviprone (ONC201) synergize to reduce renal cell carcinoma cell viability |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-03-18 | Jazz Pharmaceuticals | Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026 jazzpharma.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NUVISERTIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL3975308 ↗ |
| Known as | SGI-9481 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3975308 ↗ |
| Known as | TP-3654 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03715504 ↗ |
| Action | Inhibit | “oral PIM inhibitor” NCT03715504 ↗ |
| Modality | Small molecule | — CHEMBL3975308 ↗ |
| Route | Oral | “TP-3654 by oral administration” NCT03715504 ↗ |